Genetic, Epigenetic and Pharmacogenetic Aspects of Psoriasis and Psoriatic Arthritis

Rheumatic Disease Clinics of North America

Volumn 41, Issue 4, 2015, Pages 623-642

  O'Rielly, Darren D ^a   Rahman, Proton ^b  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Candidate genes; Epigenetics; Genetics; GWAS; Pharmacogenetics; Psoriasis; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; HLA B27 ANTIGEN; HLA B38 ANTIGEN; HLA B39 ANTIGEN; HLA B8 ANTIGEN; HLA C ANTIGEN; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB;

ANTIGEN PRESENTATION; DNA METHYLATION; EPIGENETICS; EPISTASIS; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENETICS; GENOTYPE; HERITABILITY; HUMAN; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; PHARMACOGENETICS; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REVIEW; TH1 CELL; TH17 CELL; ARTHRITIS, PSORIATIC; GENETIC PREDISPOSITION; GENOME-WIDE ASSOCIATION STUDY; IMMUNOLOGY; PROCEDURES;

ARTHRITIS, PSORIATIC; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNITY, INNATE; PHARMACOGENETICS; PSORIASIS;

EID: 84945469805     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2015.07.002     Document Type: Review

References (154)

1. Chandran V., Schentag C.T., Brockbank J.E., et al. Familial aggregation of psoriatic arthritis. Ann Rheum Dis 2009, 68:664-667.
2. Nair R.P., Stuart P.E., Nistor I., et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 2006, 78:827-851.
3. Eder L., Chandran V., Pellett F., et al. Differential human leucocyte allele association between psoriasis and psoriatic arthritis: a family-based association study. Ann Rheum Dis 2012, 71:1361-1365.
4. Gudjonsson J.E., Karason A., Runarsdottir E.H., et al. Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients-an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol 2006, 126:740-745.
5. Eder L., Chandran V., Gladman D.D. What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis?. Curr Opin Rheumatol 2015, 27:91-98.
6. Winchester R., Minevich G., Steshenko V., et al. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum 2012, 64:1134-1144.
7. Haroon M., Winchester R., Giles J.T., et al. Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Ann Rheum Dis 2014, [Epub ahead of print].
8. Eder L., Chandran V., Pellet F., et al. Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. Ann Rheum Dis 2012, 71:50-55.
9. Okada Y., Han B., Tsoi L.C., et al. Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. Am J Hum Genet 2014, 95:162-172.
10. Gonzalez S., Martinez-Borra J., Torre-Alonso J.C., et al. The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Arthritis Rheum 1999, 42:1010-1016.
11. Lanier L.L. NK cell recognition. Annu Rev Immunol 2005, 23:225-274.
12. Chandran V., Bull S.B., Pellett F.J., et al. Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis. Rheumatology 2014, 53:233-239.
13. O'Rielly D.D., Rahman P. Genetics of susceptibility and treatment response in psoriatic arthritis. Nat Rev Rheumatol 2011, 7:718-732.
14. Karason A., Gudjonsson J.E., Upmanyu R., et al. A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. Am J Hum Genet 2003, 72:125-131.
15. Schroder J.M., Harder J. Human beta-defensin-2. Int J Biochem Cell Biol 1999, 31:645-651.
16. Hollox E.J., Huffmeier U., Zeeuwen P.L., et al. Psoriasis is associated with increased β defensin genomic copy number. Nat Genet 2008, 40:23-25.
17. Niyonsaba F., Ogawa H., Nagaoka I. Human β defensin 2 functions as a chemotactic agent for tumour necrosis factor α-treated human neutrophils. Immunology 2004, 111:273-281.
18. Filer C., Ho P., Smith R.L., et al. Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum 2008, 58:3705-3709.
19. Li M., Wu Y., Chen G., et al. Deletion of the late cornified envelope genes LCE3C and LCE3B is associated with psoriasis in a Chinese population. J Invest Dermatol 2011, 131:1639-1643.
20. Coto E., Santos-Juanes J., Coto-Segura P., et al. Mutation analysis of the LCE3B/LCE3C genes in Psoriasis. BMC Med Genet 2010, 11:45.
21. Riveira-Munoz E., He S.M., Escaramís G., et al. Meta-analysis confirms the LCE3C_LCE3B deletion as a risk factor for psoriasis in several ethnic groups and finds interaction with HLA-Cw6. J Invest Dermatol 2011, 131:1105-1109.
22. Labarthe M.P., Bosco D., Saurat J.H., et al. Upregulation of connexin 26 between keratinocytes of psoriatic lesions. J Invest Dermatol 1998, 111:72-76.
23. Djalilian A.R., McGaughey D., Patel S., et al. Connexin 26 regulates epidermal barrier and wound remodeling and promotes psoriasiform response. J Clin Invest 2006, 116:1243-1253.
24. Sun L.D., Cheng H., Wang Z.X., et al. Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet 2010, 42:1005-1009.
25. Hüffmeier U., Uebe S., Ekici A.B., et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 2010, 42:996-999.
26. Tsoi L.C., Spain S.L., Knight J., et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 2012, 44(12):1341-1348.
27. Ellinghaus D., Ellinghaus E., Nair R.P., et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet 2012, 90:636-647.
28. Liu Y., Helms C., Liao W., et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008, 4:e1000041.
29. Stuart P.E., Nair R.P., Ellinghaus E., et al. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 2010, 42:1000-1004.
30. Nair R.P., Duffin K.C., Helms C., et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009, 41:199-204.
31. Ellinghaus E., Ellinghaus D., Stuart P.E., et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet 2010, 42:991-995.
32. Strange A., Capon F., Spencer C.C., et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010, 42:985-990.
33. Zhang X.J., Huang W., Yang S., et al. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet 2009, 41:205-210.
34. Verstrepen L., Carpentier I., Verhelst K., et al. ABINs: A20 binding inhibitors of NF-kappa B and apoptosis signaling. Biochem Pharmacol 2009, 78:105-114.
35. Hayden M.S., Ghosh S. NF κB in immunobiology. Cell Res 2011, 21:223-244.
36. Orozco G., Eyre S., Hinks A., et al. Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 2011, 70:463-468.
37. Vereecke L., Beyaert R., van Loo G. Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease. Biochem Soc Trans 2011, 39:1086-1091.
38. Nititham J., Taylor K.E., Gupta R., et al. Meta-analysis of the TNFAIP3 region in psoriasis reveals a risk haplotype that is distinct from other autoimmune diseases. Genes Immun 2015, 16:120-126.
39. De Molfetta G.A., Lucíola Zanette D., Alexandre Panepucci R., et al. Role of NFKB2 on the early myeloid differentiation of CD34+ hematopoietic stem/progenitor cells. Differentiation 2010, 80:195-203.
40. Lowenstein C.J., Padalko E. iNOS (NOS2) at a glance. J Cell Sci 2004, 117:2865-2867.
41. Strobl B., Stoiber D., Sexl V., et al. Tyrosine kinase 2 (TYK2) in cytokine signaling and host immunity. Front Biosci 2011, 16:3214-3232.
42. Blonska M., Lin X. NF-κB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res 2011, 21(1):55-70.
43. Lu T., Jackson M.W., Wang B., et al. Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc Natl Acad Sci U S A 2010, 107:46-51.
44. Orian A., Whiteside S., Israël A., et al. Ubiquitin-mediated processing of NF-kappa B transcriptional activator precursor p105. Reconstitution of a cell-free system and identification of the ubiquitin-carrier protein, E2, and a novel ubiquitin-protein ligase, E3, involved in conjugation. J Biol Chem 1995, 270(37):21707-21714.
45. Zhou Z., Hamming O.J., Ank N., et al. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 2007, 81(14):7749-7758.
46. Gotoh K., Tanaka Y., Nishikimi A., et al. Selective control of type I IFN induction by the Rac activator DOCK2 during TLR-mediated plasmacytoid dendritic cell activation. J Exp Med 2010, 207(4):721-730.
47. Negishi H., Osawa T., Ogami K., et al. A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. Proc Natl Acad Sci U S A 2008, 105(51):20446-20451.
48. Piganis R.A., De Weerd N.A., Gould J.A., et al. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. J Biol Chem 2011, 286(39):33811-33818.
49. Bijlmakers M.J., Kanneganti S.K., Barker J.N., et al. Functional analysis of the RNF114 psoriasis susceptibility gene implicates innate immune responses to double-stranded RNA in disease pathogenesis. Hum Mol Genet 2011, 20(16):3129-3137.
50. Veale D.J., Barnes L., Rogers S., et al. Immunohistochemical markers for arthritis in psoriasis. Ann Rheum Dis 1994, 53(7):450-454.
51. Pitzalis C., Cauli A., Pipitone N., et al. Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis. Arthritis Rheum 1996, 39(1):137-145.
52. Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect 2009, 11(5):625-630.
53. Bowcock A.M., Shannon W., Du F., et al. Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet 2001, 10(17):1793-1805.
54. Kersh E.N. Impaired memory CD8 T cell development in the absence of methyl-CpG-binding domain protein 2. J Immunol 2006, 177(6):3821-3826.
55. Zamisch M., Tian L., Grenningloh R., et al. The transcription factor Ets1 is important for CD4 repression and Runx3 up-regulation during CD8 T cell differentiation in the thymus. J Exp Med 2009, 206(12):2685-2699.
56. Chang I.F., Hsiao H.Y. Induction of RhoGAP and pathological changes characteristic of Alzheimer's disease by UAHFEMF discharge in rat brain. Curr Alzheimer Res 2005, 2(5):559-569.
57. Togayachi A., Kozono Y., Kuno A., et al. Beta3GnT2 (B3GNT2), a major polylactosamine synthase: analysis of B3GNT2-deficient mice. Methods Enzymol 2010, 479:185-204.
58. Yan J., Parekh V.V., Mendez-Fernandez Y., et al. In vivo role of ER associated peptidase activity in tailoring peptides for presentation by MHC class Ia and class Ib molecules. J Exp Med 2006, 203(3):647-659.
59. Ryan C., Abramson A., Patel M., et al. Current investigational drugs in psoriasis. Expert Opin Investig Drugs 2012, 21(4):473-487.
60. Liang J., Wang J., Azfer A., et al. A novel CCCH-zinc finger protein family regulates proinflammatory activation of macrophages. J Biol Chem 2008, 283(10):6337-6346.
61. Robinson R.T. IL12Rβ1: the cytokine receptor that we used to know. Cytokine 2015, 71(2):348-359.
62. Wei L., Laurence A., O'Shea J.J. New insights into the roles of Stat5a/b and Stat3 in T cell development and differentiation. Semin Cell Dev Biol 2008, 19(4):394-400.
63. Marcoulatos P., Avgerinos E., Tsantzalos D.V., et al. Mapping interleukin enhancer binding factor 3 gene (ILF3) to human chromosome 19 (19q11-qter and 19p11-p13.1) by polymerase chain reaction amplification of human-rodent somatic cell hybrid DNA templates. J Interferon Cytokine Res 1998, 18(5):351-355.
64. Cheung P.F., Wong C.K., Lam C.W. Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23: implication for Th17 lymphocytes-mediated allergic inflammation. J Immunol 2008, 180:5625-5635.
65. Bulek K., Liu C., Swaidani S., et al. The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation. Nat Immunol 2011, 12:844-852.
66. Sønder S.U., Saret S., Tang W., et al. IL-17-induced NF-kappaB activation via CIKS/Act1: physiologic significance and signaling mechanisms. J Biol Chem 2011, 286:12881-12890.
67. Fujioka S., Niu J., Schmidt C., et al. NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. Mol Cell Biol 2004, 24:7806-7819.
68. Chiricozzi A., Guttman-Yassky E., Suárez-Farias M., et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011, 131:677-687.
69. Zaba L.C., Suárez-Fariñas M., Fuentes-Duculan J., et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009, 124:1022-1030.
70. Tesmer L.A., Lundy S.K., Sarkar S., et al. Th17 cells in human disease. Immunol Rev 2008, 223:87-113.
71. Flisiak I., Chodynicka B., Porebski P., et al. Association between psoriasis severity and transforming growth factor beta(1) and beta (2) in plasma and scales from psoriatic lesions. Cytokine 2002, 19:121-125.
72. Flisiak I., Zaniewski P., Chodynicka B. Plasma TGF-beta1, TIMP-1, MMP-1 and IL-18 as a combined biomarker of psoriasis activity. Biomarkers 2008, 13:549-556.
73. Nockowski P., Szepietowski J.C., Ziarkiewicz M., et al. Serum concentrations of transforming growth factor beta 1 in patients with psoriasis vulgaris. Acta Dermatovenerol Croat 2004, 12:2-6.
74. Lindroos J., Svensson L., Norsgaard H., et al. IL-23-mediated epidermal hyperplasia is dependent on IL-6. J Invest Dermatol 2011, 131:1110-1118.
75. Yang X.P., Ghoreschi K., Steward-Tharp S.M., et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 2011, 12:247-254.
76. Boca A.N., Talamonti M., Galluzzo M., et al. Genetic variations in IL6 and IL12B decreasing the risk for psoriasis. Immunol Lett 2013, 156:127-131.
77. Di Cesare A., Di Meglio P., Nestle F.O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009, 129:1339-1350.
78. Korn T., Bettelli E., Oukka M., et al. IL-17 and Th17 Cells. Annu Rev Immunol 2009, 27:485-517.
79. Blumberg H., Dinh H., Dean C., et al. IL-1RL2 and its ligands contribute to the cytokine network in psoriasis. J Immunol 2010, 185:4354-4362.
80. Julià A., Tortosa R., Hernanz J.M., et al. Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes. Hum Mol Genet 2012, 21:4549-4557.
81. Rahman P., Sun S., Peddle L., et al. Association between the interleukin-1 family gene cluster and psoriatic arthritis. Arthritis Rheum 2006, 54:2321-2325.
82. Ravindran J.S., Owen P., Lagan A., et al. Interleukin 1alpha, interleukin 1beta and interleukin 1 receptor gene polymorphisms in psoriatic arthritis. Rheumatology (Oxford) 2004, 43:22-26.
83. Bowes J., Ho P., Flynn E., et al. Investigation of IL1, VEGF, PPARG and MEFV genes in psoriatic arthritis susceptibility. Ann Rheum Dis 2012, 71:313-314.
84. Oppmann B., Lesley R., Blom B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
85. Pappu R., Ramirez-Carrozzi V., Sambandam A. The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology 2011, 134:8-16.
86. Szodoray P., Alex P., Chappell-Woodward C.M., et al. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford) 2007, 46:417-425.
87. Lee E., Trepicchio W.L., Oestreicher J.L., et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004, 199:125-130.
88. Tang C., Chen S., Qian H., et al. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology 2012, 135:112-124.
89. Langrish C.L., Chen Y., Blumenschein W.M., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240.
90. Harris T.J., Grosso J.F., Yen H.R., et al. Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 2007, 179:4313-4317.
91. Tanaka K., Ichiyama K., Hashimoto M., et al. Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads. J Immunol 2008, 180:3746-3756.
92. Moisan J., Grenningloh R., Bettelli E., et al. Ets-1 is a negative regulator of Th17 differentiation. J Exp Med 2007, 204:2825-2835.
93. Novatchkova M., Leibbrandt A., Werzowa J., et al. The STIR-domain superfamily in signal transduction, development and immunity. Trends Biochem Sci 2003, 28:226-229.
94. Toy D., Kugler D., Wolfson M., et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 2006, 177:36-39.
95. Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?. Cytokine 2008, 41:84-91.
96. Chabaud M., Lubberts E., Joosten L., et al. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001, 3:168-177.
97. Raychaudhuri S.P., Raychaudhuri S.K., Genovese M.C. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 2012, 359:419-429.
98. Mrabet D., Laadhar L., Sahli H., et al. Synovial fluid and serum levels of IL-17, IL-23, and CCL-20 in rheumatoid arthritis and psoriatic arthritis: a Tunisian cross-sectional study. Rheumatol Int 2013, 33:265-266.
99. Tonel G., Conrad C., Laggner U., et al. Cutting edge: a critical functional role for IL-23 in psoriasis. J Immunol 2010, 185:5688-5691.
100. Wilson N.J., Boniface K., Chan J.R., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007, 8:950-957.
101. Feinberg M.W., Cao Z., Wara A.K., et al. Kruppel-like factor 4 is a mediator of proinflammatory signaling in macrophages. J Biol Chem 2005, 280(46):38247-38258.
102. Huber M., Brüstle A., Reinhard K., et al. IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype. Proc Natl Acad Sci U S A 2008, 105(52):20846-20851.
103. Ammar M., Bouchlaka-Souissi C., Zaraa I., et al. Family-based association study in Tunisian familial psoriasis. Int J Dermatol 2012, 51:1329-1334.
104. Catanoso M.G., Boiardi L., Macchioni P., et al. IL-23A, IL-23R, IL-17A and IL-17R polymorphisms in different psoriatic arthritis clinical manifestations in the northern Italian population. Rheumatol Int 2013, 33:1165-1176.
105. Prans E., Kingo K., Traks T., et al. Copy number variations in IL22 gene are associated with Psoriasis vulgaris. Hum Immunol 2013, 74:792-795.
106. Tohyama M., Hanakawa Y., Shirakata Y., et al. IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression. Eur J Immunol 2009, 39:2779-2788.
107. Saeki H., Hirota T., Nakagawa H., et al. Genetic polymorphisms in the IL22 gene are associated with psoriasis vulgaris in a Japanese population. J Dermatol Sci 2013, 71:148-150.
108. Yang X.O., Pappu B.P., Nurieva R., et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008, 28:29-39.
109. Korn T., Bettelli E., Gao W., et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448:484-487.
110. Nurieva R., Yang X.O., Martinez G., et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007, 448:480-483.
111. Caruso R., Botti E., Sarra M., et al. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 2009, 15:1013-1015.
112. He Z., Jin L., Liu Z.F., et al. Elevated serum levels of interleukin 21 are associated with disease severity in patients with psoriasis. Br J Dermatol 2012, 167:191-193.
113. Warren R.B., Smith R.L., Flynn E., et al. A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21. Br J Dermatol 2011, 164:660-664.
114. Bowes J., Orozco G., Flynn E., et al. Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Ann Rheum Dis 2011, 70:1641-1644.
115. Zhu K.J., Zhu C.Y., Shi G., et al. Association of IL23R polymorphisms with psoriasis and psoriatic arthritis: a meta-analysis. Inflamm Res 2012, 61:1149-1154.
116. Cénit M.C., Ortego-Centeno N., Raya E., et al. Influence of the STAT3 genetic variants in the susceptibility to psoriatic arthritis and Behcet's disease. Hum Immunol 2013, 74:230-233.
117. Leipe J., Grunke M., Dechant C., et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010, 62(10):2876-2885.
118. van Kuijk A.W., Reinders-Blankert P., Smeets T.J., et al. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006, 65(12):1551-1557.
119. Yago T., Nanke Y., Kawamoto M., et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther 2007, 9(5):R96.
120. Gottlieb A., Menter A., Mendelsohn A., et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009, 373(9664):633-640.
121. Gervin K., Vigeland M.D., Mattingsdal M., et al. DNA methylation and gene expression changes in monozygotic twins discordant for psoriasis: identification of epigenetically dysregulated genes. PLoS Genet 2012, 8(1):e1002454.
122. Gudjonsson J.E., Krueger G. A role for epigenetics in psoriasis: methylated Cytosine-Guanine sites differentiate lesional from nonlesional skin and from normal skin. J Invest Dermatol 2012, 132(3 Pt 1):506-508.
123. Duffin K.C., Freeny I.C., Schrodi S.J., et al. Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking. J Invest Dermatol 2009, 129(12):2777-2783.
124. Eder L., Chandran V., Pellett F., et al. IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients. Ann Rheum Dis 2011, 70(9):1594-1598.
125. Chatterjee R., Vinson C. CpG methylation recruits sequence specific transcription factors essential for tissue specific gene expression. Biochim Biophys Acta 2012, 1819(7):763-770.
126. Zhang P., Su Y., Chen H., et al. Abnormal DNA methylation in skin lesions and PBMCs of patients with psoriasis vulgaris. J Dermatol Sci 2010, 60(1):40-42.
127. Han J., Park S.G., Bae J.B., et al. The characteristics of genome-wide DNA methylation in naïve CD4+ T cells of patients with psoriasis or atopic dermatitis. Biochem Biophys Res Commun 2012, 422(1):157-163.
128. Roberson E.D., Liu Y., Ryan C., et al. A subset of methylated CpG sites differentiate psoriatic from normal skin. J Invest Dermatol 2012, 132(3 Pt 1):583-592.
129. Gu X., Nylander E., Coates P.J., et al. Correlation between reversal of DNA methylation and clinical symptoms in psoriatic epidermis following narrow-band UVB phototherapy. J Invest Dermatol 2015, 135(8):2077-2083.
130. Hou R., Yin G., An P., et al. DNA methylation of dermal MSCs in psoriasis: identification of epigenetically dysregulated genes. J Dermatol Sci 2013, 72(2):103-109.
131. Zhang P., Zhao M., Liang G., et al. Whole-genome DNA methylation in skin lesions from patients with psoriasis vulgaris. J Autoimmun 2013, 41:17-24.
132. Park G.T., Han J., Park S.G., et al. DNA methylation analysis of CD4+ T cells in patients with psoriasis. Arch Dermatol Res 2014, 306(3):259-268.
133. Mizutani H., Ohmoto Y., Mizutani T., et al. Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J Dermatol Sci 1997, 14(2):145-153.
134. Anandarajah A., Ritchlin C.T. Treatment update on spondyloarthropathy. Curr Opin Rheumatol 2005, 17(3):247-256.
135. Gottlieb A.B., Leonardi C.L., Goffe B.S., et al. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol 2006, 54(Suppl):S92-S100.
136. Krueger G.G., Langley R.G., Finlay A.Y., et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005, 153:1192-1199.
137. Moore A., Gordon K.B., Kang S., et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007, 56:598-603.
138. Gottlieb A.B., Masud S., Ramamurthi R., et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003, 48:68-75.
139. Menter A., Gottlieb A., Feldman S.R., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008, 58(5):826-850.
140. Menter A., Tyring S.K., Gordon K., et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2007, 58:106-115.
141. Seitz M., Wirthmüller U., Möller B., et al. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 2007, 46:93-96.
142. Murdaca G., Gulli R., Spanò F., et al. TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis. J Invest Dermatol 2014, 134:2503-2509.
143. Morales-Lara M.J., Cañete J.D., Torres-Moreno D., et al. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine 2012, 79:591-596.
144. Pundt N., Peters M.A., Wunrau C., et al. Susceptibility of rheumatoid arthritis synovial fibroblasts to FasL- and TRAIL-induced apoptosis is cell cycle-dependent. Arthritis Res Ther 2009, 11:R16.
145. Hofbauer L.C., Schoppet M., Christ M., et al. Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. Rheumatology (Oxford) 2006, 45:1218-1222.
146. Batalla A., Coto E., González-Fernández D., et al. The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients. Pharmacogenet Genomics 2015, 25(6):313-316.
147. Ramírez J., Fernández-Sueiro J.L., López-Mejías R., et al. FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-α blockers in psoriatic arthritis: a longitudinal study with 6 months of followup. J Rheumatol 2012, 39:1035-1041.
148. Gottlieb A.B., Chamian F., Masud S., et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005, 175:2721-2729.
149. Krueger G.G., Langley R.G., Leonardi C., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007, 356(6):580-592.
150. Chien A.L., Elder J.T., Ellis C.N. Ustekinumab: a new option in psoriasis therapy. Drugs 2009, 69(9):1141-1152.
151. Chen X., Tan Z., Yue Q., et al. The expression of interleukin-23 (p19/p40) and inteleukin-12 (p35/p40) in psoriasis skin. J Huazhong Univ Sci Technolog Med Sci 2006, 26(6):750-752.
152. Talamonti M., Botti E., Galluzzo M., et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol 2013, 169(2):458-463.
153. Baerveldt E.M., Onderdijk A.J., Kurek D., et al. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response. Br J Dermatol 2013, 168(5):990-998.
154. Gedebjerg A., Johansen C., Kragballe K., et al. IL-20, IL-21 and p40: potential biomarkers of treatment response for ustekinumab. Acta Derm Venereol 2013, 93(2):150-155.